Drug Type Recombinant polypeptide, Biosimilar |
Synonyms Semaglutide Biosimilar (Chongqing Paijin Biotechnology Co Ltd.), semaglutide biosimilar(Huadong Medicine/Chongqing Peg-Bio BioPharma), 司美格鲁肽 生物类似药(Chongqing Paijin Biotechnology Co Ltd.) + [4] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | China | 01 Apr 2025 | |
Obesity | Phase 3 | China | 27 Dec 2024 | |
Obesity | Phase 3 | China | 27 Dec 2024 |